Calimmune

Calimmune, Inc. was a clinical-stage gene therapy company that developed and commercialized lentiviral gene therapies for sickle cell disease and beta-thalassemia, including its lead asset CAL-H using the Select+™ stem cell gene therapy platform. The company was acquired by CSL Behring in 2017.